Business Information
The group's principal activity is to apply functional genomic technologies and Internet-based bioinformatic systems to discover and develop pharmaceutical products to treat unmet medical needs. The group operates in the genomics-based pharmaceutical industry, combining engineering principles with biology and information technology to discover and develop genomics-based pharmaceutical products. The main focus is on developing protein, antibody and small molecule therapeutics to treat major unmet medical needs including obesity and diabetes, oncology, inflammation, and central nervous system disorders. The group has established internal programs to develop products to treat metabolic diseases, cancer, inflammatory diseases, and central nervous system disorders.
|
|
Name |
Title
|
Email
|
| Robert Patricelli | Non Exec. Chmn. | N/A | | Timothy Shannon | CEO, Pres. | N/A | | David Wurzer | Exec. VP, CFO, Treasurer | N/A | | Elizabeth Whayland | Corp. Sec. a, Sr. VP - Finance | N/A | | Henri Lichenstein | VP - Product Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 39,587 | (59,839) | | 2005 | 23,531 | (73,244) | | 2004 | 6,339 | (90,397)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
